Evgen Pharma PLC
LSE:EVG

Watchlist Manager
Evgen Pharma PLC Logo
Evgen Pharma PLC
LSE:EVG
Watchlist
Price: 0.8 GBX Market Closed
Market Cap: £3.4m

Net Margin

-400.1%
Current
Improving
by 257.3%
vs 3-y average of -657.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-400.1%
=
Net Income
£-3.4m
/
Revenue
£838k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-400.1%
=
Net Income
GBX-3.4m
/
Revenue
£838k

Peer Comparison

Country Company Market Cap Net
Margin
UK
Evgen Pharma PLC
LSE:EVG
3.4m GBP
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
173.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 97% of companies in United Kingdom
Percentile
3rd
Based on 3 670 companies
3rd percentile
-400.1%
Low
-188 120% — 0%
Typical Range
0% — 0.1%
High
0.1% — 10 443.9%
Distribution Statistics
United Kingdom
Min -188 120%
30th Percentile 0%
Median 0%
70th Percentile 0.1%
Max 10 443.9%

Evgen Pharma PLC
Glance View

Market Cap
3.4m GBX
Industry
Biotechnology

Evgen Pharma Plc is a clinical stage drug development company, which engages in the development of pharmaceutical products and focus on cancer and neurological disease. The company is headquartered in Wilmslow, Cheshire and currently employs 8 full-time employees. The company went IPO on 2015-10-21. The firm is developing sulforaphane-based medicines focused on the treatment of cancer and inflammation. The firm's pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01 for the treatment of metastatic breast cancer and acute respiratory distress syndrome. The SFX-01 reduces the number of cancer stem cells in patient-derived breast cancer tissue in xenograft models. Its SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin.

EVG Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-400.1%
=
Net Income
£-3.4m
/
Revenue
£838k
What is Evgen Pharma PLC's current Net Margin?

The current Net Margin for Evgen Pharma PLC is -400.1%, which is above its 3-year median of -657.4%.

How has Net Margin changed over time?

Over the last 3 years, Evgen Pharma PLC’s Net Margin has increased from -1 522.2% to -400.1%. During this period, it reached a low of -1 522.2% on Sep 30, 2020 and a high of -400.1% on Oct 30, 2023.

Back to Top